Paper Details

  1. Home
  2. Paper Details

The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.

Author: BleyzacN

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Individualized dosing of busulfan and cyclosporine using Bayesian methods significantly improved 90-day VOD-free survival and GVHD outcome in patients undergoing allogeneic HSCT.
Paper Details　
Original Abstract of the Article :
Overall survival after allogeneic haematopoietic stem cell transplantation (HSCT) is reduced by the high rate of transplantation-related mortality (TRM), especially because of liver veno-occlusive disease (VOD) or acute graft-vs.-host disease (GVHD) because of the toxicity or inefficacy of busulfan ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1472-8206.2008.00652.x

データ提供：米国国立医学図書館（NLM）

Pharmacokinetic Models in Pediatric Onco-Hematology: Optimizing Busulfan and Cyclosporine

Pediatric onco-hematology is a specialized field focused on the diagnosis and treatment of cancers affecting children. This study, published in the journal [Journal name], examines the use of pharmacokinetic models in optimizing the treatment of children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) using the drugs busulfan and cyclosporine (CsA). The researchers investigated the impact of individualized dosing based on pharmacokinetic modeling on the clinical outcome of these patients.

Optimizing Dosing for Enhanced Outcomes

The study demonstrates that individualized dosing of busulfan and CsA, based on pharmacokinetic models, significantly improves clinical outcomes in children undergoing HSCT. The researchers found that this approach led to a higher 90-day VOD-free survival rate and reduced the incidence of severe GVHD. This research underscores the importance of using pharmacokinetic models to tailor treatment regimens to the specific needs of each patient, maximizing efficacy and minimizing adverse events.

Precision Medicine in Pediatric Onco-Hematology

This study highlights the growing field of precision medicine in pediatric onco-hematology. The use of pharmacokinetic models to optimize drug dosing represents a significant advancement in personalized medicine. This approach allows for more precise treatment strategies, potentially leading to improved outcomes and reduced complications for children undergoing HSCT.

Dr. Camel's Conclusion

Just as a camel's ability to adapt to the harsh desert environment allows it to thrive, optimizing treatment regimens based on individual needs is crucial for success in pediatric onco-hematology. This study highlights the value of pharmacokinetic models in achieving personalized and effective treatment, leading to improved outcomes for children facing the challenges of cancer.

Date :
  1. Date Completed 2009-02-17
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

19049662

DOI: Digital Object Identifier

10.1111/j.1472-8206.2008.00652.x

Related Literature

Article Analysis
・Effects of busulfan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.